MA45498A - Cellules treg génétiquement modifiées - Google Patents

Cellules treg génétiquement modifiées

Info

Publication number
MA45498A
MA45498A MA045498A MA45498A MA45498A MA 45498 A MA45498 A MA 45498A MA 045498 A MA045498 A MA 045498A MA 45498 A MA45498 A MA 45498A MA 45498 A MA45498 A MA 45498A
Authority
MA
Morocco
Prior art keywords
genetically modified
treg cells
modified treg
cells
genetically
Prior art date
Application number
MA045498A
Other languages
English (en)
Inventor
Takatoshi Chinen
Alexander Y Rudensky
Original Assignee
Memorial Sloan Kettering Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Memorial Sloan Kettering Cancer Center filed Critical Memorial Sloan Kettering Cancer Center
Publication of MA45498A publication Critical patent/MA45498A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/416—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0637—Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
MA045498A 2016-06-16 2017-06-15 Cellules treg génétiquement modifiées MA45498A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662351104P 2016-06-16 2016-06-16

Publications (1)

Publication Number Publication Date
MA45498A true MA45498A (fr) 2019-04-24

Family

ID=60663377

Family Applications (1)

Application Number Title Priority Date Filing Date
MA045498A MA45498A (fr) 2016-06-16 2017-06-15 Cellules treg génétiquement modifiées

Country Status (8)

Country Link
US (1) US20190322983A1 (fr)
EP (1) EP3472305A4 (fr)
JP (2) JP2019518460A (fr)
CN (1) CN109415698A (fr)
AU (1) AU2017285319A1 (fr)
CA (1) CA3027546A1 (fr)
MA (1) MA45498A (fr)
WO (1) WO2017218850A1 (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017342176A1 (en) * 2016-10-10 2019-05-02 The National Institute for Biotechnology in the Negev Ltd. Non-cytotoxic modified cells and use thereof
GB201714718D0 (en) 2017-09-13 2017-10-25 Autolus Ltd Cell
US20210017248A1 (en) * 2018-03-16 2021-01-21 The Regents Of The University Of California Cellular signaling domain engineering in chimeric antigen receptor-modified regulatory t cells
CN112955174A (zh) 2018-07-09 2021-06-11 旗舰先锋创新V股份有限公司 融合剂脂质体组合物和其用途
GB201814203D0 (en) 2018-08-31 2018-10-17 King S College London Engineered regulatory t cell
AU2019378883A1 (en) 2018-11-14 2021-06-03 Flagship Pioneering Innovations V, Inc. Fusosome compositions for T cell delivery
BR112021014442A2 (pt) * 2019-02-01 2021-09-21 KSQ Therapeutics, Inc. Composições de regulação gênica e métodos para imunoterapia aprimorada
WO2021007396A2 (fr) * 2019-07-09 2021-01-14 The Children's Mercy Hospital Lymphocytes t régulateurs modifiés
US20230060230A1 (en) * 2020-01-27 2023-03-02 H. Lee Moffitt Cancer Center And Research Institute, Inc. Hdac6-inhibited human regulatory t cells
CN115427440A (zh) * 2020-02-25 2022-12-02 圭尔医疗有限公司 用于工程化细胞的嵌合受体
GB202102637D0 (en) 2021-02-24 2021-04-07 Quell Therapeutics Ltd Engineered regulatory t cell
EP4403580A1 (fr) 2023-01-23 2024-07-24 Medizinische Hochschule Hannover Anti-entpd3 récepteur antigénique chimérique
CN120981484A (zh) 2023-01-23 2025-11-18 汉诺威医学院 抗entpd3嵌合抗原受体
AU2024219048A1 (en) 2023-02-07 2025-08-07 Quell Therapeutics Limited Culture method for treg cells
WO2024175805A1 (fr) 2023-02-24 2024-08-29 Medizinische Hochschule Hannover Récepteur antigénique chimérique
EP4420676A1 (fr) 2023-02-24 2024-08-28 Medizinische Hochschule Hannover Récepteur antigénique chimérique
EP4680728A1 (fr) 2023-03-17 2026-01-21 Quell Therapeutics Limited Thérapie treg
WO2024194355A1 (fr) 2023-03-20 2024-09-26 Medizinische Hochschule Hannover Récepteur antigénique chimérique
EP4434539A1 (fr) 2023-03-20 2024-09-25 Medizinische Hochschule Hannover Récepteur antigénique chimérique
WO2026008994A1 (fr) 2024-07-04 2026-01-08 Quell Therapeutics Limited Construction d'expression
GB202411558D0 (en) 2024-08-06 2024-09-18 Quell Therapeutics Ltd Culture method

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6235873B1 (en) * 1999-07-31 2001-05-22 The Rockefeller University Constitutively active transcription factors and their uses for identifying modulators of activity including dysproliferative cellular changes
EP2167647A2 (fr) * 2007-06-13 2010-03-31 La Jolla Institute For Allergy And Immunology Lymphocytes t régulateurs et procédé pour les préparer et les utiliser
US8658159B2 (en) * 2008-06-30 2014-02-25 Versitech Limited Method to induce and expand therapeutic alloantigen-specific human regulatory T cells in large-scale
EP4166148B1 (fr) * 2014-06-06 2026-02-18 Memorial Sloan-Kettering Cancer Center Récepteurs d'antigènes chimères à mésothéline ciblée et leurs utilisations
US20180134795A1 (en) * 2014-06-17 2018-05-17 Cellectis Cd123 specific multi-chain chimeric antigen receptor
US11111505B2 (en) * 2016-03-19 2021-09-07 Exuma Biotech, Corp. Methods and compositions for transducing lymphocytes and regulating the activity thereof

Also Published As

Publication number Publication date
CA3027546A1 (fr) 2017-12-21
JP2019518460A (ja) 2019-07-04
CN109415698A (zh) 2019-03-01
US20190322983A1 (en) 2019-10-24
EP3472305A1 (fr) 2019-04-24
WO2017218850A1 (fr) 2017-12-21
AU2017285319A1 (en) 2018-12-20
JP2022058995A (ja) 2022-04-12
EP3472305A4 (fr) 2020-01-15

Similar Documents

Publication Publication Date Title
EP3472305A4 (fr) Cellules treg génétiquement modifiées
IL262772A (en) Genetically engineered cells and methods of making the same
NO2025012I1 (no) Autologous anti-CD19-transduced CD3+ cells (brexucabtagene autoleucel)
EP3562492A4 (fr) Cellules tueuses naturelles génétiquement modifiées
IL292828A (en) Central memory t cells for adoptive t cell therapy
MA46959A (fr) Cellules b modifiées et compositions et méthodes associées
IL259586B (en) Genetically modified stem cells and uses thereof
IL262359A (en) Ex vivo bite-activated t cells
EP3471772A4 (fr) Compositions et méthodes de déplétion de cellules
EP3858365C0 (fr) Lymphocytes t car optimisés avec de l'or
EP3411079A4 (fr) Cellules mammifères génétiquement modifiées pour thérapie anticancéreuse
EP3507831A4 (fr) Cellules de mémoire et matrices mémoire
IL254734B1 (en) Modified t cells and methods of making and using the same
EP3507832A4 (fr) Cellules de mémoire et matrices mémoire
EP3443506C0 (fr) Neurone artificiel
EP4212613C0 (fr) Matrice de croissance cellulaire
EP3426690A4 (fr) Cellules effectrices immunes éditées par le génome
HUE053101T2 (hu) Javított T-sejt-készítmények
IL249970B (en) Gamma delta t cells and uses thereof
EP3573464A4 (fr) Ingénierie de cellules b
EP3475413C0 (fr) Lymphocytes t génétiquement modifiés
IL261710A (en) Production of antigen-specific t-cells
EP3455344A4 (fr) Cellules souches/progénitrices hématopoïétiques
HUE053760T2 (hu) SUV39h1-deficiens immunsejtek
EP3475986A4 (fr) Interconnexion cellule-à-cellule